Lucas Michel Todó

Lucas Michel Todó

Auto-generated profile, based on publicly available information

Lucas Michel Todó

Systems Oncology Program, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
OLOriol Llorà-Batlle
Oriol Llorà-Batlle
LMLucas Michel-Todó
Lucas Michel-Todó
KWKathrin Witmer
Kathrin Witmer
HTHaruka Toda
Haruka Toda
MBMaria Carmen Fernandez Becerra
Maria Carmen Fernandez Becerra
ACAlfred Cortés
Alfred Cortés
Malaria transmission requires that some asexual parasites convert into sexual forms termed gametocytes. The initial stages of sexual development, including sexually committed schizonts and sexual rings, remain poorly characterized, mainly because they are morphologically identical to their asexual counterparts and only a small subset of parasites undergo sexual development. Here, we describe a system for controlled sexual conversion in the human malaria parasite Plasmodium falciparum, based on conditional expression of the PfAP2-G transcription factor. Using this system, ~90 percent of the parasites converted into sexual forms upon induction, enabling the characterization of committed and early sexual stages without further purification. We characterized sexually committed schizonts and sexual rings at the transcriptomic and phenotypic levels, which revealed down-regulation of genes involved in solute transport upon sexual commitment, among other findings. The new inducible lines will facilitate the study of early sexual stages at additional levels, including multiomic characterization and drug susceptibility assays.

14 February 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
LMLucas Michel-Todó
Lucas Michel-Todó
CBCristina Bancells
Cristina Bancells
NCNúria Casas-Vila
Núria Casas-Vila
NRNúria Rovira-Graells
Núria Rovira-Graells
CHCarles Hernández-Ferrer
Carles Hernández-Ferrer
ACAlfred Cortés
Alfred Cortés
The survival of malaria parasites in the changing human blood environment largely depends on their ability to alter gene expression by epigenetic mechanisms. The active state of Plasmodium falciparum clonally variant genes (CVGs) is associated with euchromatin characterized by the histone mark H3K9ac, whereas the silenced state is characterized by H3K9me3-based heterochromatin.

8 October 2025 in Cancer Discovery
Verified
Journal Article
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo. Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.

6 February 2026
Verified
Other
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
Frequency of AR H875Y mutations and HLA allotypes in the Abida and colleagues, 2019 Cohort

6 February 2026
Verified
Other
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
Retroviral transduction of Jurkat (TCR alpha beta KO) CD8+ T-cells with AR H875Y specific TCRs

6 February 2026
Verified
Other
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
HLA-B*15:01 Binding Predictions for AR H875Y by NetMHCpan 8 to 14 flanking the mutation